NAD+ Metabolism: The Cellular Budget Behind Energy, DNA Repair and Aging

A cell can have fuel available and still struggle to produce ATP. It can also spend heavily on DNA repair while leaving less NAD+ available for other processes. These are different problems, even though both involve the same molecule.

That is what makes NAD+ metabolism more interesting than the usual “energy and longevity” story. NAD+ connects the extraction of energy from food with the maintenance of the machinery doing the work. But its concentration, location, recycling rate and consumption all matter. Simply increasing one blood measurement cannot tell us whether that entire system works better.

For readers in Vancouver and across Canada comparing NAD+, NMN and mitochondrial research, the useful starting question is therefore: which part of the system is actually limiting function? Following NAD+ through the cell reveals why the answer is rarely just “more NAD+.”

NAD+ versus NADH: the difference is an electron transfer

Nicotinamide adenine dinucleotide is a coenzyme made from two linked nucleotide units. One contains adenine; the other contains nicotinamide, whose ring performs the crucial redox chemistry.

NAD+ is the oxidized form. During many metabolic reactions, an enzyme transfers a hydride—two electrons and one proton—from a substrate to the nicotinamide ring, producing NADH. NADH can subsequently donate those electrons and regenerate NAD+. The “+” describes the conventional oxidized nicotinamide form; it does not mean that the entire molecule has a net positive charge at physiological pH. [1]

The chemical shorthand is NAD+ + H+ + 2 electrons ⇌ NADH. In an actual cell, enzymes couple this transfer to oxidation or reduction of another molecule. Electrons do not simply float around waiting to be collected.

The distinction matters because pool size and redox balance are different measurements. A cell can contain substantial total NAD(H), yet have too little oxidized NAD+ available relative to NADH for particular reactions. Conversely, a favourable ratio does not guarantee an adequate total pool. There is no single ideal NAD+/NADH ratio for every cellular compartment.

Figure 1. Redox cycling regenerates NAD+. It is chemically different from the NAD+-consuming reactions involved in signalling and repair.

From glucose to ATP: where NAD+ actually participates

Glycolysis and the mitochondrial entry gate

In the cytosol, glycolysis converts one glucose molecule into two pyruvate molecules, with a net production of two ATP. At the glyceraldehyde-3-phosphate dehydrogenase step, NAD+ accepts electrons, producing two NADH per glucose. Glycolysis needs NAD+ regeneration to continue. Lactate dehydrogenase can perform that regeneration by reducing pyruvate to lactate; lactate formation is therefore part of redox management, not simply metabolic failure. [1, 2]

Pyruvate enters the mitochondrial matrix through transport machinery that includes the mitochondrial pyruvate carrier, MPC1/MPC2. NAD+ is not the carrier or a molecular bouncer admitting pyruvate. Its role becomes especially clear after entry, when the pyruvate dehydrogenase complex converts pyruvate into acetyl-CoA, releases carbon dioxide and reduces NAD+ to NADH. [3]

Cytosolic NADH also does not freely cross the inner mitochondrial membrane. The malate–aspartate and glycerol-3-phosphate shuttles transfer its reducing equivalents through linked reactions. Depending on the shuttle, electrons enter mitochondrial respiration through different routes. [1]

The citric acid cycle loads the carriers

Acetyl-CoA supplies a two-carbon unit to the citric acid cycle. Each turn produces three NADH at the NAD+-dependent isocitrate dehydrogenase, α-ketoglutarate dehydrogenase and malate dehydrogenase reactions. It also produces a GTP or ATP equivalent and transfers electrons through enzyme-bound FAD at succinate dehydrogenase, which is respiratory Complex II. [2]

These reactions collect energy from fuel oxidation in transferable chemical form. NADH is not ATP, and NAD+ is not fuel in the same sense as glucose or fatty acids. The NAD+/NADH pair repeatedly connects the reactions that release electrons with those that use their energy.

Complex I, proton pressure and the ATP turbine

At Complex I, mitochondrial NADH is oxidized back to NAD+. Its electrons pass through internal cofactors to ubiquinone. Electron transfer continues through Complex III, cytochrome c and Complex IV, where oxygen is reduced to water. Complexes I, III and IV couple electron transfer to proton movement from the matrix toward the intermembrane space. Complex II supplies electrons to ubiquinone but does not pump protons. [4]

The inner membrane thereby stores energy as an electrochemical gradient: both a difference in proton concentration and an electrical potential. Protons returning through ATP synthase drive rotation and conformational changes that allow ADP and inorganic phosphate to form ATP. Oxygen is the final electron acceptor; it is not directly consumed by ATP synthase. [4]

A useful mechanical analogy is a pump-and-turbine installation. Fuel oxidation supplies electron-bearing carriers. Respiratory complexes use the released energy to pump protons uphill. The inner membrane retains that gradient, and ATP synthase harvests the downhill flow. NADH is part of the energy-transfer system, not the turbine itself.

If the membrane leaks excessively, respiratory complexes are damaged, oxygen is limited or ADP supply is inadequate, adding more carrier does not necessarily fix output. NAD+ availability and mitochondrial efficiency are related, but they are not interchangeable.

Figure 2. Electrons and protons follow different routes. The membrane separates compartments so the proton gradient can do useful work.

Location matters: the cell does not have one NAD+ tank

Nuclear, cytosolic and mitochondrial NAD+ pools are connected but differently regulated. Compartment-targeted biosensors helped establish that local free NAD+ concentrations cannot be inferred from a single whole-cell measurement. “Free” NAD+ available to enzymes is also not identical to every molecule recovered in a tissue extract. [5]

A major advance came in 2020 with identification of SLC25A51 as a mammalian mitochondrial NAD+ transporter. In cell experiments, reducing this transporter lowered mitochondrial NAD+ and impaired respiration without necessarily lowering whole-cell NAD+. A seemingly normal overall reading could therefore conceal a mitochondrial shortage. [6]

This finding does not prove that injected NAD+ travels intact from blood into every mitochondrion. SLC25A51 addresses transport across the inner mitochondrial membrane; getting from an administration site into blood, across a cell membrane and into the relevant compartment involves additional steps.

An unusually revealing 2024 study engineered compartment-specific NAD+ consumption in cultured cells. The cells tolerated substantial chronic depletion better when the mitochondrial pool was protected. The experiments also implicated SLC25A51 and, where present, reversible NMNAT3 chemistry in buffering NAD+ availability. This is evidence about cellular adaptation—not proof that a particular percentage decline is harmless in humans. It nevertheless makes location a more informative question than a universal depletion number. [7]

The NAD+ economy: recycling is different from spending

The central accounting distinction is between redox turnover and molecular consumption. NAD+ becoming NADH does not destroy the coenzyme. Oxidation returns it to service. By contrast, sirtuins, PARPs and CD38 cleave NAD+, requiring replacement through biosynthesis. [8]

Think of a workshop with reusable tools and a repair budget. Redox cycling repeatedly uses the tools. NAD+-consuming reactions dismantle some tools to support signalling or maintenance, while biosynthesis rebuilds the stock. The workshop needs both activities; preventing every expenditure would disable useful functions.

Salvage, synthesis and the cost of rebuilding

The salvage pathway recycles nicotinamide, also called NAM. NAMPT combines NAM with phosphoribosyl pyrophosphate to form NMN. NMNAT enzymes then use ATP to convert NMN into NAD+, releasing pyrophosphate. NR enters through phosphorylation by nicotinamide riboside kinases before the NMNAT step. These routes depend on enzymes and metabolic resources, not merely precursor supply. [8]

Cells can also synthesize NAD+ from tryptophan through the kynurenine pathway, quinolinate, nicotinic acid mononucleotide and nicotinic acid adenine dinucleotide. Nicotinic acid enters through the separate Preiss–Handler route. Different tissues contribute differently to whole-body precursor handling: isotope-tracing experiments in mice identified the liver as an important source of circulating nicotinamide derived from tryptophan. [8]

A concentration is a snapshot of inventory. Flux is the rate of production and consumption. McReynolds and colleagues found that NAD+ synthesis flux was maintained in many aged mouse tissues despite lower concentrations. Low inventory did not automatically mean that the synthetic machinery had stopped working. [9]

Inflammation can increase demand

CD38 is an NAD+-consuming enzyme involved in immune and calcium signalling. In mouse and cell studies, inflammatory signals from senescent cells promoted CD38-expressing macrophages, linking the tissue environment to increased NAD+ consumption. Senescent cells can therefore influence neighbouring cells' metabolic conditions, rather than aging being exclusively an isolated intracellular problem. [10]

This does not make CD38 useless or establish that blocking it is a general longevity strategy. It shows why supplying more precursor and reducing excessive consumption are biologically distinct research questions.

The budget also changes with time of day. Mouse studies connected CLOCK–BMAL1 regulation of NAMPT with oscillations in NAD+ and feedback through SIRT1. Circadian timing can influence measurements and experimental interpretation. Those findings do not establish a universally optimal supplement time in humans. [11]

Figure 3. A simplified pathway map. Redox cycling preserves NAD(H); consuming enzymes cleave NAD+ and release nicotinamide for potential salvage.

DNA repair and sirtuins: maintenance has a metabolic price

SIRT1, SIRT3 and SIRT6 do different jobs

Sirtuins are NAD+-dependent enzymes, not a single anti-aging switch. In deacylation reactions, they remove chemical groups from proteins while consuming NAD+. Their effects depend on the enzyme, substrate, compartment and cellular state.

SIRT1 helps coordinate nutrient-responsive gene regulation. Experimental work links SIRT1-mediated regulation of PGC-1α to mitochondrial and fatty-acid oxidation programmes in muscle cells. This connects metabolic state to changes in gene expression; it does not mean that NAD+ administration automatically creates more functional mitochondria. [12]

SIRT3 regulates mitochondrial protein acetylation. Experiments involving SOD2, a mitochondrial antioxidant enzyme, demonstrate one route through which SIRT3 can affect reactive oxygen species handling. Reactive oxygen species also have signalling functions, so “eliminating all ROS” would be an inaccurate description of healthy mitochondrial regulation. [13]

SIRT6 acts prominently in chromatin regulation and genome maintenance. In cellular experiments it promoted DNA repair under stress through interaction with PARP1. Separate cell research links SIRT6-mediated histone deacetylation to telomeric chromatin stability and prevention of replication-associated telomere defects. [27] These mechanisms help explain links between NAD+ availability, chromatin—the DNA–protein packaging system—and repair responses. They do not establish that supplementation lengthens human telomeres or reverses biological aging. [14]

PARP activity illustrates the repair trade-off

PARP1 detects particular forms of DNA damage and uses NAD+ to build ADP-ribose modifications involved in coordinating the response. This is useful spending. With extensive damage, however, high consumption can strain NAD+ availability and increase the burden of resynthesis. Repair capacity and metabolic capacity can therefore become coupled. [1, 14]

Mitochondrial quality control likewise involves several systems: biogenesis, protein maintenance, mitochondrial dynamics and removal of damaged organelles. NAD+-dependent regulation intersects with this network, but no single concentration measurement captures its effectiveness. NAD+ is a resource used by maintenance machinery, not a substitute for that machinery.

Aging evidence: which tissue, which outcome?

NAD+ biology intersects with skeletal muscle function, metabolic regulation, inflammation, senescence and neurological disease. The strongest interpretation remains specific to the experiment. Age effects differ with tissue, species, health status, cell composition and measurement method; the mouse flux study is a useful warning against treating every lower concentration as the same defect. [9]

Muscle: a randomized crossover study in 12 older men found that oral NR altered the muscle NAD+ metabolome, including related metabolites, without improving measured mitochondrial bioenergetics. The distinction between a metabolite response and improved respiration is central, not a footnote. [15]

Metabolic regulation: a randomized trial in postmenopausal women with prediabetes found improved muscle insulin sensitivity after NMN supplementation. That is a specific human physiological finding. It does not establish general fat loss, diabetes reversal or improved function in every population. [16]

Neurological research: the phase I NADPARK trial studied oral NR in people with Parkinson's disease and reported variable increases in cerebral NAD and associated metabolic responses. It investigated biological target engagement and early clinical signals; it did not establish prevention of neurodegeneration or restored cognition in healthy adults. [17]

Inflammation and senescence: the CD38 work provides a mechanistic link between inflammatory cells and tissue NAD+ decline. Human proof that an NAD+-raising intervention interrupts that entire aging process is a separate evidentiary requirement. [10]

For interpreting such distinctions, our guide to human, animal and in-vitro research evidence explains why an impressive molecular result cannot automatically support a clinical promise.

NAD+ delivery and bioavailability: five routes, different evidence

“Bioavailability” needs a specified molecule and endpoint. Intact precursor in plasma, NAD+ in blood cells, NAD+ in muscle and a functional improvement are not the same measurement. Comparisons that mix these endpoints can make one route appear superior without actually testing superiority.

Oral NAD+

NAD+ can undergo breakdown before and during absorption, and extracellular metabolism complicates delivery of the intact molecule to cells. Human evidence connecting ordinary oral NAD+ formulations with reproducible target-tissue effects is limited relative to NR. However, breakdown is not synonymous with biological uselessness: components may enter salvage pathways. Evidence about oral NR or NMN cannot simply be assigned to a product containing NAD+ itself. [1, 8]

Nicotinamide riboside: NR

Oral NR can raise blood-cell NAD+ markers in humans; Martens and colleagues demonstrated this in a randomized trial of middle-aged and older adults. Metabolism along the gut–liver–tissue route means that intact NR in plasma is only part of the story. Some material reaches tissues through downstream metabolites. The muscle trial discussed above shows why successful biochemical delivery does not guarantee improved respiration. [8, 15, 18]

Nicotinamide mononucleotide: NMN

NMN is a direct biosynthetic precursor of NAD+, but oral administration does not mean every molecule reaches every tissue intact. Conversion to other precursors and tissue-specific processing complicate its pharmacokinetics. Nevertheless, controlled human studies have reported increased blood NAD+ after oral NMN, and the prediabetes trial detected a muscle insulin-sensitivity effect. The claim that oral NMN is completely ineffective is inconsistent with these findings. Neither finding demonstrates longer human lifespan. [16, 19]

Intravenous NAD+

IV administration puts NAD+ directly into the circulation, which is why IV systemic bioavailability is conventionally 100%. That definition says nothing about the fraction entering muscle cells or mitochondria intact. A small human infusion study measured changes in plasma and urine NAD-related metabolites; it did not establish complete intracellular delivery or clinical rejuvenation. Extracellular breakdown, uptake and excretion all affect interpretation. [20]

Subcutaneous NAD+

Subcutaneous administration places material in tissue beneath the skin, from which absorption must still occur. Bypassing digestion alone cannot establish nearly 100% absolute bioavailability. A convincing estimate would require a suitable exposure comparison with IV administration, dose normalization and analytical methods that distinguish administered NAD+ from endogenous pools and metabolites.

The research search through 16 October 2026 did not identify a peer-reviewed human study establishing that near-complete figure. A 2026 preliminary safety preprint includes injectable NR and NAD+ comparisons, including subcutaneous administration, but it is not proof of near-100% NAD+ bioavailability or superior clinical outcomes. NR injection research must also not be relabelled as NAD+ injection evidence. [21]

The route question therefore remains conditional: which compound reaches which compartment, and does the measured outcome improve? Existing studies do not justify declaring subcutaneous NAD+ the only effective approach.

SS-31, BPC-157 and growth-hormone-releasing peptides

The idea of combining compounds becomes persuasive when each appears to address a different part of mitochondrial biology. But complementary descriptions are not evidence of a successful combination.

SS-31, or elamipretide, has a relatively direct mitochondrial rationale. Preclinical research demonstrated interactions with cardiolipin and effects on cytochrome c-associated membrane chemistry. This concerns the membrane environment supporting respiration, whereas NAD+ supplies redox and enzymatic functions. Their conceptual relationship is plausible, but a clinically proven synergistic NAD+/SS-31 combination does not follow. In the phase III MMPOWER-3 trial, elamipretide did not improve the primary walking-distance and fatigue endpoints in the overall primary mitochondrial myopathy population. That result illustrates why mechanism and clinical outcome must be examined separately. [22, 23]

BPC-157 has preclinical research involving vascular signalling, including VEGFR2–Akt–eNOS activity in endothelial systems and injury models. Blood supply and nitric oxide biology can influence tissue metabolism, but this is an indirect connection. Those experiments do not establish direct NAD+ replenishment, improved human mitochondrial efficiency or synergy with NAD+. [24]

CJC-1295 without DAC requires particular naming care. The often-cited human CJC-1295 trial studied a long-acting albumin-binding analogue. Its exposure and growth-hormone/IGF-1 findings cannot be transferred to a no-DAC product commonly described as modified GRF(1–29). Neither establishes that adding it to NAD+ improves longevity. [25]

Sermorelin, a GHRH(1–29) analogue, acts through the pituitary growth-hormone axis rather than directly rebuilding NAD+. An older randomized GHRH study using sermorelin reported selected cognitive improvements, but did not test a NAD+ combination, mitochondrial NAD+ restoration or lifespan extension. Hormonal effects and direct mitochondrial effects should remain distinct. [26]

A useful combination study would compare each component and the combination, measure relevant tissue endpoints and assess whether any additional benefit exceeds the effects of the individual agents. A collection of separate studies cannot do that job.

Questions that sharpen NAD+ research

Can a blood NAD+ test reveal my mitochondrial NAD+ level?

Not directly. Whole blood, plasma and isolated blood cells represent different samples, and none is a direct measurement of mitochondrial NAD+ in muscle or brain. Compartment-specific findings explain why the distinction matters. [5, 6]

Does more NAD+ mean less oxidative stress?

Not automatically. Oxidative stress depends on oxidant production, antioxidant systems and cellular context. SIRT3-related regulation is one connection, but it does not turn the NAD+ concentration into a universal oxidative-stress score. [13]

Is NAD+ a peptide?

No. It is a dinucleotide coenzyme. A research supplier may list it alongside peptides, but chemical identity and study evidence remain separate. Our NAD+ 500 mg research material information describes that distinction; the listing is not evidence of clinical effectiveness.

What should a convincing NAD+ study measure next?

A strong design links exposure, tissue-specific target engagement and meaningful function, with appropriate controls and sufficient follow-up. It asks whether respiration, insulin sensitivity, physical performance or another prespecified outcome changes—not just whether a blood biomarker rises.

The most revealing NAD+ question is not how high a number can go. It is whether the right pool is available, recycled and replenished where the cell needs it, while the machinery using that pool remains capable of useful work.

Scientific references

1. Yang & Sauve (2016). NAD+ metabolism: Bioenergetics, signaling and manipulation for therapy. — Biochemical review.

2. Alberts et al. How Cells Obtain Energy from Food. Molecular Biology of the Cell. — Biochemistry textbook.

3. Bricker et al. (2012). A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. — Primary mechanistic research.

4. Alberts et al. The Mitochondrion. Molecular Biology of the Cell. — Biochemistry textbook.

5. Cambronne et al. (2016). Biosensor reveals multiple sources for mitochondrial NAD+. — Cellular biosensor research.

6. Luongo et al. (2020). SLC25A51 is a mammalian mitochondrial NAD+ transporter. — Primary cellular research.

7. Høyland et al. (2024). Subcellular NAD+ pools are interconnected and buffered by mitochondrial NAD+. — Engineered cell systems and modelling.

8. Liu et al. (2018). Quantitative analysis of NAD synthesis-breakdown fluxes. — Cellular and mouse isotope tracing.

9. McReynolds et al. (2021). NAD+ flux is maintained in aged mice despite lower tissue concentrations. — Mouse aging and isotope tracing.

10. Covarrubias et al. (2020). Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. — Mouse and cellular research.

11. Ramsey et al. (2009). Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. — Mouse and mechanistic research.

12. Gerhart-Hines et al. (2007). Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. — Primary mechanistic research.

13. Qiu et al. (2010). Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. — Preclinical mechanistic research.

14. Mao et al. (2011). SIRT6 promotes DNA repair under stress by activating PARP1. — Cellular DNA repair research.

15. Elhassan et al. (2019). Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. — Human randomized crossover trial.

16. Yoshino et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. — Human randomized trial.

17. Brakedal et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. — Human phase I trial.

18. Martens et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. — Human randomized trial.

19. Okabe et al. (2022). Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. — Human controlled trial.

20. Grant et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. — Small human pharmacokinetic pilot.

21. Preliminary Safety Analysis of Two Pilot Clinical Trials Involving Injections of Niagen®, Nicotinamide Riboside Chloride (2026). — PREPRINT — not peer reviewed.

22. Birk et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. — Preclinical mechanistic research.

23. Karaa et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. — Human phase III randomized trial.

24. Hsieh et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. — Preclinical vascular research.

25. Teichman et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. — Human trial — long-acting analogue.

26. Vitiello et al. (2006). Growth hormone releasing hormone improves the cognition of healthy older adults. — Human controlled trial.

27. Michishita et al. (2008). SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. — Primary cellular research.